Clinical trial

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

Recruiting now · Phase 4 · 1 countries · Registry ID NCT07247084

Recruiting nowPhase 4Interventional

What this study is about

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionObesity

Full registry criteria

Inclusion Criteria: * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by \>0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity) Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening

Treatments and study arms

Tirzepatide

Drug

Administered SC

Standard of Care

Other

Standard of care

Primary outcomes

Percent Change from Baseline in Body WeightBaseline, 24 months

Study locations

30 locations were listed when this page was built. The first 40 are shown.

P91604 St John's Medical Centre🇬🇧 Altrincham, United Kingdom